Tyra biosciences to present preclinical data on tyra-300, an fgfr3-selective inhibitor, at esmo 2022 congress

Carlsbad, calif. , sept. 5, 2022 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the company will be presenting preclinical data on tyra-300 during a poster session at the european society for medical oncology (esmo) 2022 congress, being held in person september 9-13, 2022 in paris, france.
TYRA Ratings Summary
TYRA Quant Ranking